Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications; it’s time for a break …

November 10, 2017 7:50am

From the loss-per-share releases as spending and cash positions set expectation

As development platform progressions affect a yawn

And investors’ debate staying as more than some clinical trials have trouble populating

Can’t read because of no subscription - you’re missing situational awareness and the most trustworthy source of independent insight!

Pre-open trading indications: 3 SELLs and 1 BUY

For continued access to what one industry CEO calls the “bible” for smart investing in the RegMed, gene and cell therapy sector’ … I’d recommend being a subscriber!

Is the truth so hard to fathom?

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

5 hours 45 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.